Holen Sie sich die Stockscreener-App
24.20
0.75%
0.18
Handel nachbörslich:
24.20
Schlusskurs vom Vortag:
$24.02
Offen:
$24.49
24-Stunden-Volumen:
1.53M
Relative Volume:
1.17
Marktkapitalisierung:
$2.13B
Einnahmen:
$172.60M
Nettoeinkommen (Verlust:
$-285.42M
KGV:
-7.3416
EPS:
-3.2963
Netto-Cashflow:
$-323.17M
1W Leistung:
+2.33%
1M Leistung:
+16.63%
6M Leistung:
+61.01%
1J Leistung:
+80.06%
1-Tages-Spanne:
$24.03
$25.59
1-Wochen-Bereich:
$23.32
$25.59
52-Wochen-Spanne:
$8.58
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
24.20 | 2.12B | 172.60M | -285.42M | -323.17M | -3.2963 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Hedge Fund Bets: Is Syndax Pharmaceuticals Inc stock showing strong momentumMarket Trend Summary & Daily Price Action Insights - baoquankhu1.vn
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Hudson Bay Capital Management LP - MarketBeat
CEO Moves: Can Syndax Pharmaceuticals Inc stock double in the next yearMarket Activity Report & Community Verified Watchlist Alerts - baoquankhu1.vn
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset - The Motley Fool
DAFNA Capital Reduces Syndax Pharmaceuticals Holding in Q4 2025News and Statistics - IndexBox
Kynam Capital Sells $8.18M in Syndax Shares, Position Value RisesNews and Statistics - IndexBox
Biotech Shares Surge 72% with $8 Million Transaction, Yet This Is Why a Fund Remains Optimistic - Bitget
Understanding Momentum Shifts in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals stock hits 52-week high at 25.16 USD By Investing.com - Investing.com Canada
Can Syndax Pharmaceuticals Inc scale operations efficiently2026 News Drivers & Fast Moving Stock Watchlists - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week HighWhat's Next? - MarketBeat
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q4 2025 earnings preview - MSN
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? - Yahoo Finance
Kingdon Capital Management L.L.C. Purchases 400,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Granahan Investment Management LLC Has $6.10 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Algert Global LLC Cuts Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Assessing Whether Syndax Pharmaceuticals (SNDX) Still Looks Undervalued After Its Recent Strong Run - simplywall.st
Syndax Pharmaceuticals, Inc. $SNDX Position Reduced by Prosight Management LP - MarketBeat
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Its 81.5% One Year Share Price Gain - simplywall.st
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
SNDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Syndax Pharmaceuticals at Barclays Conference: Strategic Growth Focus - Investing.com
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (SNDX) Movement - Stock Traders Daily
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - The Globe and Mail
Syndax Pharmaceuticals stock hits 52-week high at $22.91 By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - MarketBeat
SNDX: JP Morgan Raises Price Target to $45Maintains Overweigh - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year HighStill a Buy? - MarketBeat
Syndax Pharmaceuticals : SNDX - 24/7 Wall St.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Wall Street Zen Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Hold - MarketBeat
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating - MSN
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push - TipRanks
Can Syndax Pharmaceuticals Inc. stock maintain growth trajectory2026 Momentum Check & AI Forecasted Stock Moves - Naître et grandir
Syndax Pharmaceuticals, Inc. $SNDX is Knott David M Jr's 7th Largest Position - MarketBeat
Vanguard Group Inc. Buys 104,683 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Market Wrap: Is Syndax Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Bitget
Syndax Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Syndax Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-03-03 - Seeking Alpha
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):